Our Phosphodiesterase 7 (PDE7) program is based on our discoveries of previously unknown links between PDE7 and any addiction or compulsive disorder and between PDE7 and any movement disorders, such as Parkinson's disease (PD). PDE7 appears to modulate the dopaminergic system, which plays a significant role in regulating both addiction and movement. Data generated in preclinical studies support both of these potential indications. We have selected a clinical candidate and are conducting additional studies evaluating the effects of potential clinical candidates in models of addiction and compulsive disorders as well as PD.

Patent Position

Omeros owns two pending U.S. patent applications and 12 pending international patent applications directed to the link between PDE7 and movement disorders as well as two pending U.S. patent applications directed to the link between PDE7 and addiction and compulsive disorders. Additionally, under a license we exclusively control rights to two issued U.S. patents and ten issued and 13 pending patent applications in foreign markets that claim proprietary PDE7 inhibitors.